Janux Therapeutics, Inc. (JANX)

Janux Therapeutics, Inc. (JANX) is a healthcare company (biotechnology) based in the United States. The share price is $10.69, down 2.11% on the day, which values the company at $654.05M. Price as of 17 Nov 2026, 19:30 UTC, from Yahoo Finance.

Key facts

Share price
$10.69−2.11% today
Market value
$654.05M
Funk Score
42/100
Against its own history
Well below its usual priceusual price $17.88
200-week average
$24.6157% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Janux Therapeutics, Inc. in more detail

JANX trades at -4.2× next year's expected earnings, 28.1× sales. Measured against its own history, the price is 40% below what its usual multiples would imply ($17.88) — well below its usual price. It sits 57% below its 200-week average of $24.61.

Its Funk Score is 42 out of 100 (financial strength 7.5, profitability 0.0, growth 4.3, value 5.0, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.

1 of the superinvestors tracked here hold JANX, including Peter Kolchinsky (1.5% of the portfolio).

Superinvestors holding JANX

1 of the investors tracked here report a position in their latest 13F filing.

Janux Therapeutics, Inc. (JANX): questions and answers

What is Janux Therapeutics, Inc.'s market cap?

Janux Therapeutics, Inc. is valued at $654.05M at a share price of $10.69.

Is JANX overvalued or undervalued?

Against its own history, JANX is well below its usual price: the price is 40% below the $17.88 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is JANX above its 200-week moving average?

No. JANX is 56.6% below its 200-week average of $24.61. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Janux Therapeutics, Inc. growing?

Over the last three fiscal years Janux Therapeutics, Inc.'s revenue grew 5.1% a year.

Does JANX pay a dividend?

Janux Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own JANX?

In their latest quarterly filings, Peter Kolchinsky (1.5% of the portfolio) hold JANX. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Janux Therapeutics, Inc. (JANX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/JANX

Underlying data: Yahoo Finance; company filings with the SEC.